Zinplava™ (bezlotoxumab) – Expanded indication
May 26, 2023 - The FDA approved Merck’s Zinplava (bezlotoxumab), to reduce recurrence of Clostridioides difficile infection (CDI) in adults and pediatric patients 1 year of age and older who are receiving antibacterial drug treatment for CDI and are at a high risk for CDI recurrence.
Top